Related Experiment Videos
[Antithrombotic agents in unstable angina. Review of clinical trials]
1Centre Hospitalier Emile Roux, Eaubonne.
Antithrombotic treatment of unstable angina is a highly controversial subject. The development of new antithrombotics (anti Gp IIb-IIIa, hirudin) has led to numerous therapeutic trials. Anti Gp IIb-IIIa are very promising in this indication, especially the Reopro chimeric antibody (Abciximab). Hirudin and its derivatives have demonstrated an early, but ephemeral clinical benefit. Low molecular weight heparins appear to be more effective than non-fractioned heparin and are easier and safer to use.
Antithrombotic treatment of unstable angina is a highly controversial subject. The development of new antithrombotics (anti Gp IIb-IIIa, hirudin) has led to numerous therapeutic trials. Anti Gp IIb-IIIa are very promising in this indication, especially the Reopro chimeric antibody (Abciximab). Hirudin and its derivatives have demonstrated an early, but ephemeral clinical benefit. Low molecular weight heparins appear to be more effective than non-fractioned heparin and are easier and safer to use.